J4 ›› 2014, Vol. 13 ›› Issue (4): 41-43.

• 临床医学 • 上一篇    下一篇

重组人干扰素α-1b和利巴韦林治疗儿童手足口病疗效对比研究

  

  1. 大理学院大理教学医院,云南大理 671000
  • 收稿日期:2013-09-09 出版日期:2014-04-15 发布日期:2014-04-15
  • 作者简介:易俊,副主任医师,主要从事儿科临床疾病、心理疾病研究.

Comparative Study on the Treatments for Hand- foot -mouth Disease in Children with Human Recombinant Interferon alph-1b and Ribavirin Respectively

  1. Dali Teaching Hospital of Dali University,Dali,Yunnan 671000,China
  • Received:2013-09-09 Online:2014-04-15 Published:2014-04-15

摘要:

目的:探讨重组人干扰素α-1b治疗儿童手足口病的疗效和安全性。方法:将388例手足口病患儿随机分为两组,两组患儿
给予相同的对症和支持治疗。治疗组184例用重组人干扰素α-1b肌肉注射,<1岁1 ug/(kg·d),2~10岁10 ug/d,1 次/d;对照组204例用利巴韦林〔10~15 mg/(kg·d)〕静脉滴注。结果:治疗组与对照组比较,在退热时间,手足皮疹及口腔溃疡愈合方面均优于对照组(P<0.01),除个别患儿有发热外,治疗组未发现明显副作用。结论:干扰素治疗儿童手足口病安全有效,值得临床推广使用。

关键词: 干扰素, 利巴韦林, 手足口病, 儿童

Abstract:

Objective:To discuss the effect and safety of the treatment for children's hand- foot -mouth disease with human
recombinantinterferon alph-1b. Methods:388 cases of children with hand-foot -mouth disease were randomly divided into two groups which were given the same support and symptomatic treatment. Treatment group,184 cases were treated with human recombinant interferon alph-1b,< 1,1 ug(kg·d),intramuscular,2~10 10 ug/d muscle injection,1 times a day. The control group, 204 cases were treated with ribavirin〔10~15 mg /(kg·d)〕an intravenous drip. Results:The treatment group was better than control group (P<0.01)in the defervescence time,hand,foot and skin rash and mouth ulcer healing. In addition to that the individual children have a fever;there was no obvious side effect in the treatment group. Conclusion:Interferon treatment of hand,foot and mouth disease in children is safe and effective,and is worth popularizing clinically used.

Key words: interferon, ribavirin, hand-foot- mouth disease, children

中图分类号: